Last checked at 3 Jul 2023 16:31
PDMR Dealings
Oxford, UK - 3 July 2023: Oxford Biomedica plc ("Oxford Biomedica" or " the Company") (LSE:OXB), a quality and innovation-led viral vector CDMO, today announces that Non-Executive Directors Dr. Michael Hayden, Dr Heather Preston and Catherine Moukheibir have purchased ordinary shares in the Company pursuant to a trading plan put in place on 7 October 2022.
By way of background, and as stated in the Oxford Biomedica 2021 Remuneration Policy which was approved at the 2021 Annual General Meeting, an additional fee of up to £50,000 per annum may be paid to any Non-Executive Director recruited from or based outside of the UK to reflect market levels of remuneration for Non-Executive Directors not based in the UK, subject to their agreement that the after tax amount of this additional fee will be used to acquire Oxford Biomedica shares at market value, which must be retained for at least 12 months from acquisition. The ordinary shares were all purchased at 430p and the number of ordinary shares purchased along with further information is set out in the table below:
Name of PDMR | Number of ordinary shares purchased | Number of ordinary shares now held | Total number of ordinary shares held as a percentage of the Company's share capital |
Dr. Michael Hayden | 6,684 | 17,973 | 0.019 |
Dr. Heather Preston | 6,684 | 18,298 | 0.019 |
Cathrine Moukheibir | 6,684 | 18,530 | 0.019 |
The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the number of ordinary shares purchased.
1. | Details of the Person Discharging Managerial Responsibility ("PDMR") | |||||
a) | Name | Dr. Michael Hayden | ||||
2. | Reason for the notification | |||||
a) | Position/status | Non-Executive Director
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Purchase of shares | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s)
|
| ||||
e) | Aggregated information - Aggregate volume - Aggregated total
|
6,684
£28,741.20 | ||||
f) | Date of the transaction | 2023-07-03 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR") | |||||
a) | Name | Dr. Heather Preston | ||||
2. | Reason for the notification | |||||
a) | Position/status | Non-Executive Director
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Purchase of shares | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s)
|
| ||||
e) | Aggregated information - Aggregate volume - Aggregated total
|
6,684
£28,741.20 | ||||
f) | Date of the transaction | 2023-07-03 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR") | |||||
a) | Name | Catherine Moukheibir | ||||
2. | Reason for the notification | |||||
a) | Position/status | Non-Executive Director
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Purchase of shares | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s)
|
| ||||
e) | Aggregated information - Aggregate volume - Aggregated total
|
6,684
£28,741.20 | ||||
f) | Date of the transaction | 2023-07-03 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
-Ends-
For further information, please contact: | |
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.